Tildrakizumab
Tildrakizumab is a biologic medication used to treat moderate to severe plaque psoriasis in adults. It works by targeting and blocking IL-23, a cytokine that plays a key role in the inflammatory processes underlying psoriasis.
Tildrakizumab is an injectable biologic that treats plaque psoriasis by blocking the IL-23 inflammatory pathway.
Key facts at a glance
- ATC
- L04AC17
- RxNorm
- 2053436
- Generic
- Tildrakizumab
- Class
- atc-l04
- Brands
- Ilumya
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 100mg
- Maximum
- consult physician
- Frequency
- at weeks 0 and 4, then every 12 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 100mg
- Maximum
- consult physician
- Frequency
- at weeks 0 and 4, then every 12 weeks (approved for age 18+)
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 100mg
- Maximum
- consult physician
- Frequency
- at weeks 0 and 4, then every 12 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
use only if benefits outweigh potential risks to fetus; discontinue if pregnancy detected
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
consider discontinuing therapy in second trimester if disease is controlled
routine prenatal care
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
consider discontinuation near delivery; discuss with healthcare provider
fetal monitoring and assessment of newborn
Use with caution and monitor for adverse effects.
lactation
breastfeedingnot recommended
discontinue breastfeeding during treatment or discontinue tildrakizumab; decide whether to stop nursing or stop therapy
monitor infant for signs of infection
pediatric_age
under 18 yearsnot applicable
not approved for use in patients under 18 years of age; not recommended
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
over 65 yearsno adjustment needed
can be used at standard dose; monitor for infections
general geriatric assessment
renal_impairment
mild to moderateno adjustment needed
no dose adjustment required for mild to moderate renal impairment
standard monitoring
hepatic_impairment
mild to moderateno adjustment needed
no dose adjustment required for mild to moderate hepatic impairment
standard monitoring
Statistics and clinical data
Drug class
Monoclonal antibody targeting IL-23 p19 subunit
FDA approval year
FDA approved March 2018
Primary indication
Approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy
Administration route
100 mg at weeks 0, 4, then every 12 weeks
Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
Tildrakizumab is a humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, blocking its interaction with the IL-23 receptor and inhibiting the inflammatory cascade that contributes to psoriasis
Administered as a subcutaneous injection by a healthcare provider. Patients should be monitored for infections as immunosuppression may occur. Not recommended for use with live vaccines. Common side effects may include upper respiratory infections and injection site reactions.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy